Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 221 UK small molecule drug companies below.
Generic injectable medicines for NHS secondary care
Bowmed Ibisqus is a privately owned pharmaceutical company supplying generic injectable medicines to NHS hospitals and the private healthcare sector. Operating as a marketing authorisation holder and distributor, the company specialises in injectable antibacterials spanning penicillin, cephalosporin, macrolide, and…
Small molecule drug discovery focused on fibrosis and oncology
Redx Pharma is a clinical-stage biotech developing novel small molecule therapeutics for fibrotic disease and cancer. Its pipeline is anchored by zelasudil, a selective ROCK2 inhibitor in clinical development for idiopathic pulmonary fibrosis and other fibrotic indications, and zamaporvint, a Porcupine inhibitor…
AI-driven drug discovery targeting intrinsically disordered proteins
Peptone is a translational biophysics company developing novel therapeutics against intrinsically disordered proteins (IDPs), a class of structurally dynamic proteins implicated in cancer, inflammation and metabolic disease. The company combines hydrogen-deuterium exchange mass spectrometry, high-performance…
GPCR-targeted small molecule therapeutics
Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate G protein-coupled receptor pathways. The company targets metabolic, inflammatory, and fibrotic diseases using an integrated drug discovery platform combining…
Bioanalytical, DMPK and analytical sciences CRO for drug development
Resolian UK is a contract research organisation specialising in bioanalysis, drug metabolism and pharmacokinetics, and analytical sciences services for pharmaceutical and biotechnology clients. Operating from purpose-built laboratories in Fordham, Cambridgeshire and Sandwich, Kent, the company delivers GxP and non-GMP…
AI-driven target identification and drug discovery from omics data
Intelligent OMICS is a biotechnology company applying artificial intelligence and machine learning to drug discovery and diagnostics. Its proprietary platform analyses transcriptomic, genomic, and proteomic datasets to identify novel biological targets and disease drivers. The company offers fee-for-service target…
Small molecule drug discovery platform focused on immuno-inflammation
C4X Discovery (C4XD) is a UK drug discovery company developing small molecule drug candidates using its proprietary computational and structural chemistry platform. It applies enhanced candidate molecule design and patient stratification capabilities to generate drug candidates across immuno-inflammatory disease…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…
Manufacturer of small molecule and peptide reagents for life science research
Tocris Bioscience is a manufacturer and supplier of high-purity small molecule and peptide research reagents serving the global life science community. Its catalogue of over 4,500 products includes receptor agonists and antagonists, ion channel modulators, enzyme inhibitors, signalling pathway tools, and fluorescent…
Clinical-stage biopharma targeting cancer immunotherapy and obesity
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing small molecule therapies for high unmet medical needs. Its lead programme, POLB 001, is a p38 MAP kinase inhibitor in clinical trials for prevention of cytokine release syndrome associated with CAR-T and bispecific antibody cancer immunotherapies.…
Nanotechnology drug delivery platform for precision medicines
Nanomerics is a UK speciality pharmaceutical company developing precision medicines using its proprietary technology, a polymer nanotechnology platform that improves the bioavailability and targeting of water-insoluble drugs and peptides. The technology enables delivery via nasal, ocular, oral, and blood-brain barrier…
Small molecule inhibitors targeting somatic expansion in neurodegeneration
LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat expansion disorders. The company targets MutSβ, a protein complex whose aberrant activity drives somatic expansion and progressive…
First-in-class small molecule therapeutics targeting DNA uracilation in cancer
CV6 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule drugs for cancer and inflammatory diseases. Its lead asset CV6-168 is a specific inhibitor of the enzyme dUTPase, inducing uracil misincorporation into cancer cell DNA, triggering DNA damage and immune activation.…
High-performance counter-current chromatography instruments and services
Dynamic Extractions is a Welsh instruments and contract services company specialising in the design, manufacture, and application of High Performance Counter Current Chromatography technology. Its range of liquid-liquid separation processors enables rapid, scalable purification of complex mixtures for pharmaceutical…
First-in-class small molecule inhibitors of RNA-modifying enzymes
STORM Therapeutics is a clinical-stage biotechnology company pioneering the field of RNA epigenetics, developing small molecule inhibitors of RNA-modifying enzymes as a new class of cancer treatment. Its lead programme STC-15, a METTL3 inhibitor, was the first RNA-modifying enzyme inhibitor to enter human clinical…
Targeted protein degradation platform for neurodegenerative disease
TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional, non-aggregated forms of the same proteins. The platform is built on research into the E3 ubiquitin ligase TRIM21, conducted over nearly two…
Oncology drug discovery and IP licensing from rural Wales
Morvus Technology is a privately owned pharmaceutical company engaged in the discovery, development, and out-licensing of novel oncology drugs and platform technologies. The company's portfolio includes ProTide nucleoside chemistry, out-licensed to NuCana plc for clinical development; an inhaled anti-tumour agent for…
Tunable covalent chemistry platform for neurodegenerative disease
Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease. Its platform combines tunable covalent chemistry with targeted protein degradation, using monovalent small molecules that form durable bonds…
API and excipient supplier for pharmaceutical manufacturers
Active Pharma Supplies is a UK-based distributor and licensed repackager of active pharmaceutical ingredients and excipients, supplying hospitals, licensed specials manufacturers, pharmacies, and pharmaceutical producers. The company holds MHRA manufacturer and GDP licences and operates to EUGMP and EUGMDP quality…
Synthetic plant metabolites for osteoarthritis and age-related disease
AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage…